SAREPTA THERAPEUTICS, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
SAREPTA THERAPEUTICS, INC. (SRPT) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $73.53 million for the 3-month period ending 2018-06-30, per its 10-Q filed 2018-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-08-08
- SAREPTA THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-06-30 was $73.53M, a 110.02% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $64.60M, a 295.32% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $57.28M, a 956.58% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $45.95M.
- SAREPTA THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $154.58M, a 2751.58% increase from fiscal 2016.
- SAREPTA THERAPEUTICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $5.42M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-06-30 | $73.53M 10-Q · filed 2018-08-08 | $138.13M 10-Q · filed 2018-08-08 | $195.41M derived: sum of 3 quarters · filed 2018-08-08 | $241.36M derived: sum of 4 quarters · filed 2018-08-08 |
| 2018-03-31 | $64.60M 10-Q · filed 2018-05-03 | $121.88M derived: sum of 2 quarters · filed 2018-05-03 | $167.84M derived: sum of 3 quarters · filed 2018-05-03 | $202.85M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-12-31 | $57.28M 10-K · filed 2018-03-01 | $103.23M derived: sum of 2 quarters · filed 2018-03-01 | $138.24M derived: sum of 3 quarters · filed 2018-08-08 | $154.58M 10-K · filed 2018-03-01 |
| 2017-09-30 | $45.95M 10-K · filed 2018-03-01 | $80.97M derived: sum of 2 quarters · filed 2018-08-08 | $97.31M 10-Q · filed 2017-11-01 | $102.73M derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-06-30 | $35.01M 10-Q · filed 2018-08-08 | $51.35M 10-Q · filed 2018-08-08 | $56.77M derived: sum of 3 quarters · filed 2018-08-08 | |
| 2017-03-31 | $16.34M 10-Q · filed 2018-05-03 | $21.76M derived: sum of 2 quarters · filed 2018-05-03 | ||
| 2016-12-31 | $5.42M 10-K · filed 2018-03-01 | $5.42M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |